Weight management is the highest-volume peptide search category in Australia. Here is an honest guide to which compounds have the strongest evidence, how they work, and what proper access looks like.
This article is for general educational purposes only and does not constitute medical advice. Weight management peptides including GLP-1 receptor agonists are prescription-only medicines in Australia requiring assessment by an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
Weight management is the single highest-volume search category in the Australian peptide space as of 2025, driven primarily by the surge in public awareness of GLP-1 receptor agonists. The compounds in this category have moved from specialist clinical settings to mainstream public discussion in a short period of time, bringing both genuine clinical interest and significant misinformation in equal measure.
This guide covers the different categories of compounds studied for weight management, what the evidence actually shows, what the proper access pathway looks like in Australia, and what to consider when evaluating whether any of these approaches is appropriate for your situation.
Weight management peptides are not a single category. They include compounds with different mechanisms, different evidence bases, different regulatory statuses, and different risk profiles. Understanding which category any compound falls into is essential for evaluating the evidence and the claims made about it.
Semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) are GLP-1 receptor agonists with the most developed human clinical evidence base of any weight management compounds available in Australia. Large-scale clinical trials have produced substantial data on their effects on body weight, glucose regulation, and cardiovascular outcomes. They are TGA-registered for specific indications and are prescribed by doctors following clinical assessment. These are not compounds from the grey market. They are established medicines with significant regulatory approval and clinical use.
AOD-9604 is a synthetic fragment of human growth hormone that was specifically developed to investigate the fat metabolism effects of growth hormone without the broader hormonal effects of the full molecule. It was developed at Monash University and has been through clinical trials in Australia, including receiving TGA approval as a food additive at one point. Research has examined its interaction with fat metabolism pathways and lipolysis signalling.
Tesamorelin is a synthetic growth hormone releasing hormone analogue that has been studied and received regulatory approval in some countries for the management of visceral fat accumulation in specific clinical contexts. Research has examined its effects on IGF-1 pathways, visceral fat markers, and metabolic regulation. It has one of the more developed human clinical evidence bases of the growth hormone pathway compounds available through compounding pharmacies.
5-Amino-1MQ is a small molecule inhibitor studied for its interaction with NNMT, an enzyme involved in metabolic regulation and fat storage pathways. Research has examined its potential influence on metabolic rate and fat metabolism in preclinical models. It represents a newer area of metabolic research with an earlier-stage evidence base than the compounds above.
The evidence for GLP-1 receptor agonists in weight management is the strongest of any compound in this category. Large clinical trials have demonstrated substantial average weight loss outcomes in diverse populations, with semaglutide producing average weight loss of around 15 percent at the highest studied doses and tirzepatide producing even higher average weight loss in trials to date. These are not small effects and the evidence is robust by pharmaceutical standards.
The mechanism involves slowing gastric emptying, reducing appetite signalling centrally, and improving glucose regulation. The combined effect is reduced caloric intake without the conscious restriction that characterises dietary approaches. Side effects, particularly gastrointestinal effects during dose escalation, are well characterised and manageable under proper medical supervision.
Importantly, GLP-1 receptor agonists are prescription medicines in Australia and should be accessed through a proper medical assessment. They are not appropriate for everyone, and a doctor assessment identifies individual suitability, contraindications, and the appropriate approach to initiating and managing these medications.
Weight regain after stopping: An important and honest aspect of GLP-1 receptor agonist research is that weight regain after stopping is well documented. These compounds appear to work while being taken, with weight returning when treatment stops. This has implications for thinking about weight management as a long-term approach rather than a short course intervention, and is a reason why a doctor assessment that takes the individual's long-term health picture into account is important rather than simply accessing these compounds independently.
AOD-9604 and Tesamorelin have more developed evidence bases than most compounds discussed in weight management contexts outside the GLP-1 space. AOD-9604 has a specific Australian research history through Monash University and has been through clinical investigation in ways that give it a more established research context than many compounds discussed in this space. Tesamorelin has regulatory approval in some countries for specific visceral fat applications.
Newer compounds like 5-Amino-1MQ are at earlier research stages. The preclinical evidence is interesting to researchers, but the human clinical evidence is limited. This does not mean they are without merit, it means the evidence base is less mature and the appropriate approach is a doctor assessment of individual circumstances rather than self-directed use based on preclinical research summaries.
Weight management is an area where the consequences of getting the approach wrong can be significant. GLP-1 receptor agonists have specific contraindications, including personal or family history of certain thyroid conditions and pancreatitis history, that a doctor assessment identifies before prescribing. The dose escalation process requires monitoring for side effects. And the broader context of an individual's metabolic health, including blood glucose, blood pressure, and existing medications, all affect what is appropriate.
This is not a category where self-directed use from unregulated sources is a reasonable approach. The compounds with the strongest evidence are already prescription medicines in Australia for good reasons. The compounding pharmacy pathway provides legal access to some of these compounds where TGA-registered versions may not be readily available or accessible, but this pathway requires a valid prescription from a properly assessing doctor just as any other pharmacy does.
UHD BioHealth offers doctor-supervised access to weight management compounds through its standard assessment pathway. A prescribing doctor reviews your individual health history, current weight, metabolic markers, medications, and goals before determining what is clinically appropriate. Where GLP-1 receptor agonists are appropriate, these can be accessed through our partnered licensed compounding pharmacy. The assessment is free and there is no cost until you choose to proceed.
Start with a free assessment. A doctor reviews your health picture and determines what is clinically appropriate for your specific situation. No cost until you choose to proceed.